logo
Chicken crisis in South Africa: Here's why offal prices have skyrocketed

Chicken crisis in South Africa: Here's why offal prices have skyrocketed

The Association of Meat Importers and Exporters (AMIE) has warned of serious economic and food insecurity consequences for South Africa as a result the recent outbreak of Avian Influenza (HPAI) in the Brazilian state of Rio Grande do Sul.
Local producers cannot, and will not be able to meet the gap in supply of poultry offal (feet, gizzards, and skins) and mechanically deboned meat (MDM), driving up prices and threatening the affordability and accessibility of basic protein for millions.
Brazil is the world's largest exporter of poultry products, and accounts for 73% of poultry (excluding MDM) imported by South Africa, including frozen bone-in chicken and offal (feet, livers, necks and carcasses).
It also exports 92% of all MDM imported to South Africa, with a monthly average of 18 000 metric tons over the past year, which is vital in the production of processed meat products.
Imameleng Mothebe, CEO of AMIE, says, 'Chicken offal and MDM are not luxuries. They are foundational to school feeding programmes, and the production of processed meats which are the most affordable proteins for low-income households. Ultimately, Brazilian MDM is the source of over 400 million poultry-based meals per month for South Africa.
'Whilst we appreciate the commitment by SA poultry producers to increase their production by four million birds per month during the closure of Brazil poultry exports, the fact is that local producers alone cannot fill the gap in the production of offal and SA effectively does not produce MDM at commercial scale. In addition, alternative international markets also do not have the scale or available supply of the product mix to replace Brazil's exports to South Africa.'
The table below of official South African import statistics per month, indicates the number of chickens required per category to meet local demand for offal. Cut Description Average Metric Tonnes (Mt) Imported from Brazil Per Month Estimated Number of Chickens required Chicken Feet 4 071 54 million Chicken Livers 467 10 million Chicken Gizzards 1 505 31 million
Using the estimated output of an additional four million birds a month from local producers, and bearing in mind that the local industry will not be able to produce any additional MDM, the following shortfalls in offal per month will remain: Chicken feet – 3 773 MT tonnes per month
Gizzards – 1 315 MT tonnes per month
Livers – 287 MT tonnes per month.
Mothebe said, 'Without urgent action to put in place a regionalisation agreement with Brazil, which would allow for the import of products from areas not affected by the outbreak, price increases and food shortages for consumers, and job losses for local manufacturers of processed meats who employ over 125 000 workers, will follow.'
The economic impact of the shortfalls are already being felt in the market, warns Mothebe.
With the current shortage of MDM, processed meat producers are facing cost surges as inventory levels are thinning, and shelf prices are starting to reflect this reality.
MDM prices have surged from R13 to R31/kg, while offal like gizzards and skins have seen double-digit increases.
These increases will be compounded by rising input costs, especially with the recently announced fuel levy hike in the national budget, which adds inflationary pressure across the value chain.
This pressure will inevitably be passed on to consumers, resulting in food affordability pressures for the majority of the consumers.
Mothebe says, 'We support government continuing engagements with Brazil towards regionalisation, a concept that demarcates affected areas whilst the rest of the country remains open. Regionalisation is widely accepted and supported by the World Organisation of Animal Health (WOAH), especially in light of the ongoing global diseases phenomenon.'
Many countries are currently concluding regionalisation agreements with Brazil and therefore will soon be re-opening their markets to Brazilian imports.
This week Namibia announced the re-opening of poultry imports from Brazil as a result of concluding regionalisation agreement between the two countries.
Mothebe says, 'We urge that the conclusion of engagements between South Africa and Brazil are expedited, to minimise the impact on the South African economy and consumers alike.
'The current situation is not just a trade issue, it's about protecting jobs, businesses, consumer affordability and food security'.
Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1
Subscribe to The South African website's newsletters and follow us on WhatsApp, Facebook, X and Bluesky for the latest news.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strict SA rules keep botox treatments safe, expert says
Strict SA rules keep botox treatments safe, expert says

The Star

time20 hours ago

  • The Star

Strict SA rules keep botox treatments safe, expert says

In South Africa, as botulinum toxin injections become increasingly popular for aesthetic treatments, a recent incident in the United States has sparked renewed concerns about their potential risks. It is revealed that a mother of three from Georgia suffered partial paralysis following what was presumed to be a routine procedure, highlighting the critical importance of seeking qualified medical professionals for these treatments. The woman developed severe migraines shortly after her injections, and within a day, she was hospitalised and unable to speak or function. Medical professionals later determined that she had experienced small strokes as a result of the procedure. While such extreme complications are exceedingly rare, this case has underscored the necessity of ensuring that injectable procedures are performed only by qualified and experienced practitioners in reputable clinics. Dr JD Erasmus, MBChB, BSc, a medical doctor specialising in aesthetics, pointed out that concerns about the safety of botulinum toxin are usually unnecessary, as long as the right procedures are followed. 'People hear the word 'toxin' and understandably get nervous. But iatrogenic botulism (caused by a medical treatment) after aesthetic treatments is extremely rare in medical clinics with qualified doctors who follow proper protocols and only inject trusted products from regulated manufacturers,' he explained. Erasmus elaborated on the extensive research supporting botulinum toxin as one of the most studied anti-ageing treatments in aesthetic medicine, demonstrating its efficacy in relaxing targeted facial muscles, rejuvenating the skin, and even alleviating tension headaches. 'In cosmetic treatments, it's used in very small, highly controlled doses by trained professionals. When done correctly, it stays where it's injected, does its job, and your body naturally breaks it down over time,' he assured. Incidences of iatrogenic botulism are uncommon, with the toxin generally staying localised to treatment areas. Overall, botulism in all its forms occurs in less than one in every 100 000 cases. Dr Erasmus said that globally, thousands undergo botulinum toxin procedures safely each day, with no recorded instances linked to aesthetic treatments in South Africa as of now. However, the risks of such complications escalate in regions with weaker regulations. Just two years ago, Turkey witnessed an extreme case where 71 individuals developed iatrogenic botulism from treatments at a single clinic, calling attention to the dangers of medical tourism in poorly regulated markets. 'That's the danger of medical or cosmetic tourism to locations with less stringent safety standards,' Dr Erasmus warned. 'You may not know what product is being used or who is injecting it, and following up with your practitioner can be challenging.' South African regulations help mitigate the risks often seen abroad. Botulinum toxin injections are classified as Schedule 4 medicines regulated by the South African Health Products Regulatory Authority (SAHPRA). Only licensed doctors registered with the Health Professions Council of South Africa (HPCSA) can administer these procedures, and strict guidelines are enforced regarding the purchase and use of these products. Clinics such as the Longevity Centre at RXME prioritise patient safety through rigorous protocols, this encompasses precise temperature-controlled storage of vials, sterilisation during mixing, and thorough documentation of each product's usage. Licensed practitioners are expected to evaluate patient suitability, accurately calculate doses for optimal results, and utilise only approved products sourced from authorised suppliers. Erasmus further emphasised the importance of patients doing their due diligence prior to treatment: 'Check your practitioner's HPCSA registration, ensure that the unopened product will be used in front of you, note the lot number, and establish a clear follow-up plan.' He reassured that ethical clinics encourage such inquiries, understanding the significance of informed patients. 'Ultimately, news stories from overseas should serve as lessons about the dangers of taking shortcuts rather than prompts for panic. Botulinum toxin boasts one of the best safety records in aesthetic medicine. In South Africa, selecting a qualified doctor and a reputable clinic virtually eliminates the risk of serious complications,' Erasmus concluded. [email protected] Saturday Star

Botox treatments in South Africa: what you need to know about safety
Botox treatments in South Africa: what you need to know about safety

IOL News

time21 hours ago

  • IOL News

Botox treatments in South Africa: what you need to know about safety

Botox is widely used as an anti-ageing treatment, but there are risks if patients opt for budget deals with unregistered clinics. Image: Cottonbro studio / Pexels A South African cosmetic treatment expert says there's no need for panic here following global concerns over a recent case in the United States where a woman was left partially paralysed after having routine botulinum toxin anti-ageing injections, commonly known as Botox. And while the mother of three survived from what doctors later said was a mild stroke, it set off warning bells among thousands of people who are increasingly turning to the treatment that targets facial muscles, tightens and rejuvenates the skin. Dr J D Erasmus, a general practitioner with a special interest in aesthetics and the Head of Aesthetics at the Longevity Centre at RXME, says fears of botulism from Botox injections are largely misplaced. Dr J D Erasmus says South Africans need to be more discerning when choosing where to have cosmetic treatments. Image: Supplied Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Next Stay Close ✕ 'People hear the word 'toxin' and understandably get nervous. But iatrogenic botulism (caused by a medical treatment) after aesthetic treatments is extremely rare in medical clinics with qualified doctors who follow proper protocols and only inject trusted products from regulated manufacturers,' he says. He adds that botulinum toxin is one of the most extensively studied anti-ageing treatments in aesthetic medicine. In addition to smoothing lines and wrinkles, the treatment is also known to relieve tension headaches. 'In cosmetic treatments, it's used in very small, highly controlled doses by trained professionals. When done correctly, it stays where it's injected, does its job, and your body naturally breaks it down over time. "The horror stories we hear are almost always linked to unqualified practitioners, dangerously high doses, and fake or unregistered products, and are not the work of reputable doctors in South Africa.' In cases of iatrogenic botulism from botulinum toxin injections, the toxin moves further than the treatment area and causes muscle weakness, which is an unusual complication rarely seen in aesthetic injections, he says. 'Globally, thousands of people undergo botulinum toxin procedures safely every day. According to our research, there have not been any recorded cases linked to aesthetic treatments in South Africa. 'Overseas, however, the risks increase where regulations are weaker. "In one extreme case in Turkey two years ago, 71 people developed iatrogenic botulism from botulinum toxin injections in just over a month, and 66 of those cases were traced to the same clinic." Erasmus says this latest scare highlights the dangers associated with medical or cosmetic tourism that's poorly regulated. 'You don't always know what product is being used, who is injecting it, or whether proper safety standards are being followed, and you can't always follow up with your practitioner if you have any concerns after the procedure. 'These types of incidents are important reminders to take your health seriously and choose a clinic you can trust. Before booking a treatment, check your practitioner's qualifications and reputation and make sure that the facility follows stringent product quality and safety regulations.'

Glenmore's R2bn claims against health service providers dismissed by Competition Tribunal
Glenmore's R2bn claims against health service providers dismissed by Competition Tribunal

IOL News

timea day ago

  • IOL News

Glenmore's R2bn claims against health service providers dismissed by Competition Tribunal

The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Image: Supplied The Competition Tribunal has ruled against Glenmore Capital, dismissing its complaint regarding the alleged exclusion of its COVID-19 rapid antigen test kits from the South African public and private sectors. The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Glenmore's complaint, originally lodged with the Competition Commission in August 2022, sought damages nearing R2 billion, claiming that NHLS and AfroCentric engaged in exclusionary practices that barred it from entering the market for COVID-19 test kits. The Commission, however, chose not to pursue the case, citing Glenmore's struggle to achieve market acceptance as a result of commercial factors, including delays in regulatory approval and a decrease in demand as the COVID-19 pandemic waned. Frustrated with the Commission's decision, Glenmore escalated the matter to the Tribunal. At a pre-hearing in December 2024, Glenmore was afforded an opportunity to amend its founding affidavit to address the concerns raised by NHLS and AfroCentric. Despite making amendments, both defendants argued that Glenmore's case remained fundamentally flawed. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Next Stay Close ✕ In its defence, NHLS and AfroCentric articulated four primary exceptions, asserting that Glenmore's complaint lacked a valid cause of action, failed to properly identify the legal entities involved, lacked a clear market definition, and exceeded the Tribunal's jurisdiction due to the nature of the claims made. No valid cause of action: Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Improper citation of entities: Glenmore did not adequately identify which legal entity allegedly contravened the Act, despite having been given several opportunities to rectify this. Lack of proper market definition: The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. Lack of jurisdiction and procedural issues: The Tribunal highlighted that it cannot award damages unless under consent orders and noted allegations outside the ambit of competition law, such as irregular procurement and insider trading. The Tribunal noted that Glenmore had been granted ample opportunity to clarify and bolster its case but ultimately failed to provide a coherent argument. With the exceptions upheld, Glenmore's complaint referral was dismissed in its entirety. BUSINESS REPORT

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store